Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 12, keine Gesamtzahl für „studies“
Suchtreffer
Begriffe & Kennungen
Apretude · 4.5 · The drug interaction data provided in Table 2 is obtained from studies with oral cabotegravir (increase is ind
Eintrag öffnenApretude · 4.8 · Adverse reactions for cabotegravir were identified from the Phase III clinical studies; HPTN 083 and HPTN 084;
Eintrag öffnenApretude · 4.8 · Adverse reactions for cabotegravir were identified from the Phase III clinical studies; HPTN 083 and HPTN 084;
Eintrag öffnenAprovel · 4.5 · 57 Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan i
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAptivus · 4.5 · 8 In vitro studies show that tipranavir is a substrate and also an inhibitor of P-gp.
Eintrag öffnenAptivus · 4.5 · Interaction studies have only been performed in adults.
Eintrag öffnenAptivus · 4.5 · Studies in human liver microsomes indicated tipranavir is an inhibitor of CYP 1A2, CYP 2C9, CYP 2C19 and CYP 2
Eintrag öffnenAptivus · 4.8 · 24 Tabulated summary of adverse reactions associated with Aptivus based on clinical studies and post- marketin
Eintrag öffnenAquipta · 4.8 · In 12-week, placebo-controlled prophylaxis clinical studies, 678 patients received at least one dose of atogep
Eintrag öffnenAquipta · 4.8 · In placebo-controlled prophylaxis studies, the most commonly reported adverse reactions were nausea (9%), cons
Eintrag öffnenAqumeldi · 4.5 · Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetics (in
Eintrag öffnenAqumeldi · 4.5 · No interaction studies have been performed with AQUMELDI in the adult or paediatric population. Interaction st
Eintrag öffnenAqumeldi · 4.8 · The adverse reaction frequency listed in Table 1 is derived from the clinical studies in children receiving AQ
Eintrag öffnenAranesp · 4.8 · Data presented from controlled studies included 1,357 patients, 766 who received Aranesp and 591 patients who
Eintrag öffnenAranesp · 4.8 · In all paediatric CRF studies, there were no additional adverse reactions identified for paediatric patients c
Eintrag öffnen